April 11, 2019 09:59 AM EDTUpdated May 30, 12:13 PM
R&D

Bris­tol-My­ers de­tails its fail­ure on Check­mate 451, high­light­ing a bleak fu­ture for their check­point com­bo

John Carroll

Editor & Founder

We found out last fall that Bris­tol-My­ers Squibb’s com­bi­na­tion of its PD-1/CT­LA-4 drugs Op­di­vo and Yer­voy failed to work as a main­te­nance ther­a­py for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times